U.S. Markets open in 1 hr 13 mins
  • S&P Futures

    4,221.00
    +7.25 (+0.17%)
     
  • Dow Futures

    33,798.00
    +37.00 (+0.11%)
     
  • Nasdaq Futures

    14,175.00
    +45.00 (+0.32%)
     
  • Russell 2000 Futures

    2,280.20
    -0.70 (-0.03%)
     
  • Crude Oil

    73.02
    -0.64 (-0.87%)
     
  • Gold

    1,782.10
    -0.80 (-0.04%)
     
  • Silver

    26.00
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1903
    -0.0021 (-0.1786%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    16.81
    -3.89 (-18.79%)
     
  • GBP/USD

    1.3900
    -0.0033 (-0.2363%)
     
  • USD/JPY

    110.5570
    +0.2590 (+0.2348%)
     
  • BTC-USD

    30,218.57
    -2,209.97 (-6.81%)
     
  • CMC Crypto 200

    722.67
    -127.68 (-15.01%)
     
  • FTSE 100

    7,089.94
    +27.65 (+0.39%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

Germany says production capacity, not patents, key to upping vaccine output

·1 min read

BERLIN, May 7 (Reuters) - The main challenge to raising production of COVID-19 vaccines is how to quickly and effectively transfer technology, Germany's health minister said Friday, reiterating Berlin's opposition to a U.S. proposal to waive patent protection.

"The main issue is not patent protection but production capacity," Jens Spahn told a news conference on Friday.

In a jab at the Biden administration, Spahn also said: "I would be delighted if the United States shows the same willingness to export vaccines that we in Germany do." (Reporting by Douglas Busvine and Paul Carrel, editing by Riham Alkousaa)